Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01957735 · ClinicalTrials.gov registry record · Phase 1
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
A Phase 1 study, sponsored by BPGbio.
- Completed
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
NCT01957735 is a Phase 1 study that has completed, run by BPGbio. The registered enrollment target is 97 participants.
The verdict
NCT01957735, a Phase 1 study, has completed, sponsored by BPGbio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
Study Summary
This is a Phase 1a/b multicenter, open-label, non-randomized, dose-escalation study to examine the dose limiting toxicities (DLT) of BPM31510 administered as a 144-hour continuous intravenous (IV) infusion as monotherapy(treatment Arm 1) and in combination with chemotherapy (treatment Arm 2) in patients with solid tumors.
Interventions
- DRUG BP31510 monotherapy
- DRUG BP31510 in combination with chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2013-10 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01957735
The ClinicalTrials.gov registry entry for NCT01957735 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BPGbio, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BP31510 monotherapy is the first listed.
NCT01957735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01957735 about?
NCT01957735 is a clinical study titled "BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors". This is a Phase 1a/b multicenter, open-label, non-randomized, dose-escalation study to examine the dose limiting toxicities (DLT) of BPM31510 administered as a 144-hour continuous intravenous (IV) infusion as monotherapy(treatment Arm 1) and in combination with chemotherapy (treatment Arm 2) in pati...
What is the current status of trial NCT01957735?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2013-10. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT01957735?
The interventions under investigation include: BP31510 monotherapy (DRUG), BP31510 in combination with chemotherapy (DRUG).
Who is sponsoring clinical trial NCT01957735?
This trial is sponsored by BPGbio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.